Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumours, and in Combination With Pembrolizumab in EBV+ RM-NPC

Titre officiel

An Open-Label, Multicentre Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients With Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumours and in Combination With Pembrolizumab in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Sommaire:

This study will evaluate the safety efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive solid tumours and in combination with pembrolizumab in patients with recurrent/metastatic nasopharyngeal carcinoma

Description de l'essai

Primary Outcome:

  • Phase 1b: Incidence of dose-limiting toxicities (DLTs)
  • Phase 2: Overall response rate (ORR)
Secondary Outcome:
  • Incidence and severity of adverse events
  • Duration of response (DOR)
  • Disease control rate (DCR)
  • Progression-free survival (PFS)
  • Overall survival (OS)
  • Pharmacokinetic parameter - time to maximum plasma concentration [tmax]
  • Pharmacokinetic parameter - maximum plasma concentration [Cmax]
  • Pharmacokinetic parameter - area under the plasma concentration-time curve [AUC]

This is an open-label, multicenter Phase 1b/2 study evaluating nanatinostat in combination with valganciclovir alone and in combination with pembrolizumab. Nanatinostat is a selective class I HDAC inhibitor which induces EBV early lytic phase protein generation, activating (val)ganciclovir to its cytotoxic form.

The Phase 1b dose escalation portion is designed to evaluate safety and to determine the recommended Phase 2 dose (RP2D) in patients with EBV+ RM-NPC. In Phase 2, up to sixty patients with EBV+ RM-NPC will be randomized to receive nanatinostat in combination with valganciclovir at the RP2D with or without pembrolizumab, to evaluate safety, overall response rate, and potential pharmacodynamic markers. Additionally, patients with other EBV+ solid tumours will be enrolled to receive nanatinostat in combination with valganciclovir at the RP2D in a Phase 1b dose expansion cohort.

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer